Medicare Expansion Boosts Eli Lilly’s GLP‑1 Obesity Drug Opportunity

Medicare timetable sharpens Lilly’s GLP‑1 opportunity

Eli Lilly is positioned to gain from the imminent expansion of Medicare coverage for GLP‑1 obesity treatments, with the company expecting coverage to begin by July and adopting a bullish public tone on access. The scheduled change in U.S. reimbursement flows from the “most favored nation” pricing accords struck late last year is set to bring millions of newly eligible patients into the market, and Lilly frames the policy shift as a near‑term accelerator for prescriptions of its injectable weight‑loss treatment and forthcoming therapies.

Lilly enters the Medicare window from a position of market strength, reporting roughly 60.5% of the U.S. obesity and diabetes drug market in the latest quarter, well ahead of rivals. The company’s pipeline includes orforglipron, an oral GLP‑1 candidate expected to seek regulatory approval in the second quarter, which could complement its injectable franchise and broaden physician prescribing options if cleared. Lilly’s strategy emphasizes capturing patients across channels — Medicare, commercial and newly eligible adults — by coupling product availability with provider outreach.

Adoption still faces headwinds that shape Lilly’s near‑term rollout. Payer behavior, physician familiarity and the practicalities of scaling supply will determine how quickly Medicare beneficiaries convert to branded GLP‑1s, and Lilly is preparing for a gradual uptake similar to patterns seen in the commercially insured population. The company also contends with lower‑cost alternatives and compounded semaglutide copycats that threaten to blunt branded volumes unless payers and regulators tighten coverage and enforcement.

Novo’s oral launch and regulatory skirmishes add pressure

Novo Nordisk’s launch of the first GLP‑1 oral obesity pill and legal moves against telehealth providers intensify competition for Lilly, forcing both firms to differentiate on product profile, real‑world outcomes and access. Novo faces its own operational and reputational tests after an FDA advertising notice and litigation, and its efforts to expand production and demonstrate pill advantages create a more complex commercial landscape for Lilly to navigate.

Compounded drugs and access debates alter the market calculus

The proliferation of unapproved compounded semaglutide alternatives reshapes payer and regulatory priorities, with the industry urging enforcement to protect branded uptake. For Lilly, success depends not only on Medicare timing and product approvals but also on demonstrating clinical value, securing reliable supply chains and working with payers to limit off‑label, lower‑cost substitutes.